Hodgkin lymphoma, HIV, and Epstein–Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study
Open Access
- 26 October 2016
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (5)
Abstract
Background: Contemporary descriptions of classical Hodgkin lymphoma (cHL) are lacking from sub‐Saharan Africa where human immunodeficiency virus (HIV) and Epstein–Barr virus (EBV) are prevalent.Methods: We describe a prospective cHL cohort in Malawi enrolled from 2013 to 2015. Patients received standardized treatment and evaluation, including HIV status and EBV testing of tumors and plasma.Results: Among 31 patients with confirmed cHL, the median age was 19 years (range, 2–51 years) and 22 (71%) were male. Sixteen patients (52%) had stage III/IV, 25 (81%) B symptoms, and 16 (52%) performance status impairment. Twenty‐three patients (74%) had symptoms >6 months, and 11 of 29 (38%) had received empiric antituberculosis treatment. Anemia was common with median hemoglobin 8.2 g/dL (range, 3.1‐17.1 g/dL), which improved during treatment. No children and 5 of 15 adults (33%) were HIV+. All HIV+ patients were on antiretroviral therapy for a median 15 months (range, 2–137 months), with median CD4 count 138 cells/μL (range, 23–329 cells/μL) and four (80%) having undetectable HIV. EBV was present in 18 of 24 (75%) tumor specimens, including 14 of 20 (70%) HIV− and 4 of 4 (100%) HIV+. Baseline plasma EBV DNA was detected in 25 of 28 (89%) patients, with median viral load 4.7 (range, 2.0–6.7) log10copies/mL, and subsequently declined in most patients. At 12 months, overall survival was 75% (95% confidence interval [CI], 55%–88%) and progression‐free survival 65% (95% CI, 42%–81%). Baseline plasma EBV DNA and persistent viremia during treatment were associated with poorer outcomes.Conclusion: cHL in Malawi is characterized by delayed diagnosis and advanced disease. Most cases were EBV associated and one‐third of adults were HIV+. Despite resource limitations, 12‐month outcomes were good.Keywords
Funding Information
- National Institutes of Health (K01TW009488, R21CA180815, U54CA190152, P01CA019014)
This publication has 42 references indexed in Scilit:
- Early Experience after Developing a Pathology Laboratory in Malawi, with Emphasis on Cancer DiagnosesPLOS ONE, 2013
- Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy EraJNCI: Journal of the National Cancer Institute, 2013
- Early Age at Time of Primary Epstein–Barr Virus Infection Results in Poorly Controlled Viral Infection in Infants From Western Kenya: Clues to the Etiology of Endemic Burkitt LymphomaThe Journal of Infectious Diseases, 2012
- HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapyBlood, 2011
- Infection with human immunodeficiency virus‐1 (HIV) among children with cancer in South AfricaPediatric Blood & Cancer, 2010
- Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patientsAPMIS, 2010
- The spectrum of human immunodeficiency virus‐associated cancers in a South African black population: Results from a case–control study, 1995–2004International Journal of Cancer, 2008
- Spectrum and presentation of pediatric malignancies in the HIV era: Experience from Blantyre, Malawi, 1998–2003Pediatric Blood & Cancer, 2007
- Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDSBlood, 2006
- Pulmonary tuberculosis in children with Hodgkin's lymphomaThe Hematology Journal, 2003